Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial

NCT01329029 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01329029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01329029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2011
Completion date
May 31, 2014
Enrollment
1,945 (actual)
Sites
180

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease